US FDA Seems Ready For Return Of Zelnorm, But Seeks Advice On Best Subpopulation

Whether Sloan Pharma's irritable bowel constipation drug tegaserod should be indicated only for women at low cardiovascular risk, women who are severely symptomatic, or women who fall into both categories is a question for FDA's Gastrointestinal Drugs Advisory Committee; panel also is asked to discuss risk of psychiatric adverse events with the 5-HT4 receptor agonist.

Risk Dial

The US FDA seems prepared for the return of Zelnorm (tegaserod maleate), a treatment for irritable bowel syndrome with constipation (IBS-C), to the American market, although the agency is seeking advisory committee input on the most appropriate subpopulation for which the benefits outweigh the risks.

The Gastrointestinal Drugs Advisory Committee will convene Oct. 17 primarily to assess the 5-HT4 receptor agonist's cardiovascular (CV) risks and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers